Skip to main navigation Skip to search Skip to main content

Executive Dysfunction and Disability in SPMS: Predictive Value of the Frontal Assessment Battery in the UCLH MS-STAT2 Cohort

  • Charles Wade
  • , Anisha Doshi
  • , Sean Apap Mangion
  • , Tom Williams
  • , Alessia Bianchi
  • , Floriana De Angelis
  • , Sarah Wright
  • , Nevin John
  • , Alberto Calvi
  • , Marie Braisher
  • , James Blackstone
  • , Jennifer Nicholas
  • , Jeremy Chataway
  • , on behalf of the UCL MS-STAT2 investigators

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Introduction: Cognitive impairment is common in secondary progressive multiple sclerosis (SPMS), with executive dysfunction disproportionately so. The frontal assessment battery (FAB) is a bedside test assessing executive function. This study explores the distribution of FAB scores in a large SPMS cohort and their associations with disability. Methods: Data were analysed from 294 participants in a cognitive substudy of the MS-STAT2 trial (NCT03387670). Associations between baseline FAB scores, ambulation status (Expanded Disability Status Scale [EDSS] < 6.0 vs. ≥ 6.0) and other disability measures were assessed using generalised linear models, adjusting for age, education, gender and disease duration. FAB performance was also compared against other cognitive tests (SDMT, CVLT-II, BVMT-R). Results: 23.8% of participants scored the FAB maximum of 18; 29.9% scored below the clinical threshold of 16. FAB scores showed moderate correlations with SDMT (ρ = 0.46), CVLT-II (ρ = 0.36) and BVMT-R (ρ = 0.43), and participants scoring < 16 were significantly more likely to be impaired across these cognitive domains (p < 0.001). Lower baseline FAB scores were significantly associated with higher EDSS, slower T25FW and reduced manual dexterity (9HPT) (all p < 0.005) at baseline and longitudinally, with performance comparable to other validated cognitive tests. Conclusions: We present a large cohort of FAB scores in the SPMS population. Lower FAB scores are associated with both concurrent and future disability and may offer a scalable tool for identifying individuals at greater risk of progression and a robust trial outcome measure.

Original languageEnglish
Article numbere70286
Number of pages8
JournalEuropean Journal of Neurology
Volume32
Issue number7
DOIs
Publication statusPublished - Jul 2025
Externally publishedYes

Keywords

  • clinical trials
  • cognition
  • frontal assessment battery
  • secondary progressive multiple sclerosis

Cite this